Swixx BioPharma

حول Swixx BioPharma

Swixx BioPharma was created to replace biopharma, OTC and medical device multinationals’ subsidiaries in those countries, or therapeutic areas, that our partners choose not to enter, or to exit. Over the last ten years, we have swiftly evolved into one of the largest, most professional and reliable partners in the countries of Central & Eastern Europe, Russia/Eurasia and Greece for international healthcare companies. And we are continuing to grow. In September 2023, we opened for new opportunities in the Middle East. In May 2024, Swixx expanded to Latin America with a strategic acquisition and combination with Laboratorios Biopas SA. Through Biopas’ comprehensive Latam continental coverage, Swixx is now able to provide a compelling offering covering Central and Eastern Europe, CIS/Eurasia, MENA and Latin America.